jason luke, md: the impact of braf/mek inhibitors in melanoma
Published 7 years ago • 67 plays • Length 1:06
Download video MP4
Download video MP3
Similar videos
-
1:28
jeffrey weber, md, phd: the impact of braf/mek inhibitors in melanoma
-
1:30
dr. jason luke on sequencing targeted and immunotherapy agents in braf melanoma
-
1:42
dr. jason luke describes results from the phase iii combi-d trial
-
1:09
dr. jason luke talks about advances in how melanoma is diagnosed
-
0:56
jason luke, md: the impact of moderate level of disease burden on response to targeted therapy
-
1:31
jason j. luke, md, facp, on how data from esmo 2019 may impact the treatment of melanoma
-
0:45
jason luke, md: the role of ldh, age, and sites of disease in durability of response
-
20:21
new immune therapy for melanoma – how to know which treatment protocol will work for a patient?
-
1:31:52
sysf webinar: melanoma and non melanoma skin cancers from a to z
-
30:30
how to understand the standard of care for stage ii melanoma patients
-
1:25
dr. jason luke on potential for ido inhibitors in melanoma
-
0:45
jason luke, md: the association between durable response and low disease burden
-
0:56
jason j. luke, md, facp, on the most compelling data in metastatic melanoma from esmo 2019
-
2:05
dr. luke on challenges with immunotherapy in melanoma
-
1:30
dr. jason luke discusses nivolumab and pembrolizumab in melanoma
-
8:40
melanoma: braf/mek targeted therapy
-
7:23
melanoma: braf/mek-inhibitors as adjuvant therapy
-
0:52
jason luke, md: factors to consider when determining treatment
-
0:55
jason luke, md: durability of a response to targeted therapy combination
-
1:22
braf mutations and mek inhibitors
-
0:59
dr. luke on treatment options in metastatic melanoma
-
6:05
duration of dual braf-mek inhibition
Clip.africa.com - Privacy-policy